Immunotherapy in Renal Cell Carcinoma: The Future Is Now

Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Deleuze, Antoine, Saout, Judikaël, Dugay, Frédéric, Peyronnet, Benoit, Mathieu, Romain, Verhoest, Gregory, Bensalah, Karim, Crouzet, Laurence, Laguerre, Brigitte, Belaud-Rotureau, Marc-Antoine, Rioux-Leclercq, Nathalie, Kammerer-Jacquet, Solène-Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177761/
https://www.ncbi.nlm.nih.gov/pubmed/32260578
http://dx.doi.org/10.3390/ijms21072532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177761/
https://www.ncbi.nlm.nih.gov/pubmed/32260578
http://dx.doi.org/10.3390/ijms21072532

Ejemplares similares